Supernus Pharma (SUPN) Misses Q3 EPS by 94c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.80), $0.94 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $175.82 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Boeing wins $2 billion satellite contract from DoW
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance